Immediate vs. Extended-Release Ketamine Tablet

Immediate vs. Extended-Release Ketamine Tablet

The choice between immediate vs extended-release ketamine tablet formulations affects how quickly the drug takes effect, how strong the dissociative peak feels, and how the medication fits into an acute or maintenance treatment plan. Immediate-release (IR) ketamine tablets reach peak blood levels within 1 to 2 hours and produce a sharp, short-lived plasma peak tied to acute antidepressant and dissociative effects. Extended-release (ER) ketamine tablets release the drug over 8 to 12 hours or longer, producing steadier blood levels with a less pronounced peak. This distinction is familiar from medications like oxycodone and metformin, but it carries specific implications for ketamine because of how the drug and its active metabolite act in the brain and body.

Understanding Release Formulations

Immediate-release and extended-release describe how quickly a tablet or capsule releases its active drug into the body. Both formulation types are well established in medications such as oxycodone and metformin, and the same engineering principles apply to ketamine, with some drug-specific nuances.

Immediate-Release Ketamine Tablet

An immediate-release (IR) formulation is designed to dissolve and become available for absorption quickly after ingestion. For swallowed ketamine tablets or capsules, this means the drug becomes available for gastrointestinal absorption over roughly 30 to 90 minutes, reaching peak plasma concentration, known as Cmax, at approximately 1 to 2 hours post-dose. Cmax is the highest concentration of a drug measured in the bloodstream after a dose.

IR formulations produce a distinct plasma peak: a relatively sharp rise in blood ketamine levels followed by a decline over 3 to 5 hours. This pattern matters clinically because the acute dissociative and psychedelic effects of ketamine correlate with this peak, and the antidepressant effect appears tied to both the peak itself and the neuroplasticity it triggers afterward.

Extended-Release Ketamine Tablet

An extended-release (ER) formulation uses pharmaceutical engineering, such as matrix systems, polymer coatings, or osmotic mechanisms, to slow the release of ketamine from the tablet or capsule. Instead of a sharp peak, ER formulations produce a flatter, more sustained plasma concentration over 8 to 12 hours or longer.

ER ketamine remains an active area of pharmaceutical development. Researchers and companies are interested in ER formulations because they may:

• Reduce the intensity and frequency of dissociative side effects
• Enable once-daily or twice-daily dosing for maintenance therapy
• Provide more consistent analgesic coverage for chronic pain patients
• Reduce abuse potential compared to IR forms

Pharmacokinetic Profiles Compared

The difference in plasma concentration-time curves between IR and ER formulations has direct clinical implications for dosing, side effects, and treatment goals. According to StatPearls, ketamine's pharmacokinetics vary meaningfully by route and formulation, which is part of why prescribers weigh IR and ER options differently depending on the treatment goal. For more on how oral absorption shapes these curves, see our review of ketamine tablet bioavailability studies.

Clinical Applications

When IR Formulations Are Used

Psychiatric Treatment Sessions: Many ketamine therapy protocols, particularly those designed to produce a mild dissociative or psychedelic experience as part of therapy, favor IR formulations because the acute peak is considered therapeutically important. Some researchers believe the dissociative experience itself may enhance therapeutic processing, particularly in trauma-related conditions.

Acute Antidepressant Induction: IR ketamine is typically used during initial treatment courses aimed at rapid antidepressant response, with protocols involving daily or every-other-day dosing for 2 to 4 weeks. According to the National Institute of Mental Health, treatment-resistant depression is a recognized subset of major depressive disorder that does not respond adequately to standard antidepressant trials, and this is the population most often targeted by acute ketamine induction protocols.

Breakthrough Dosing: For chronic pain patients, IR ketamine can serve as breakthrough analgesia when baseline pain control is inadequate.

Assessment of Tolerance: When beginning ketamine tablet treatment, IR formulations let prescribers assess acute response and tolerability before committing to a longer-acting preparation.

When ER Formulations Are Used

Chronic Pain Management: Patients with continuous pain syndromes benefit from steady-state plasma levels rather than peaks and troughs. ER formulations better approximate continuous analgesia, similar to the logic behind ER opioids in pain management.

Maintenance Antidepressant Therapy: After achieving initial response with IV or IR ketamine, some protocols transition patients to ER oral formulations for maintenance. See our comparison of oral and IV ketamine for how these routes differ before a maintenance transition. The goal is to maintain neuroplastic gains without requiring repeated high-exposure sessions.

Minimizing Dissociative Side Effects: Patients who experience anxiety, derealization, or other unwanted effects at the peak of IR dosing may tolerate ER formulations better because of the blunted plasma peak.

Daily Functioning: ER ketamine may let patients take their medication at night or in the morning with less disruption to cognitive function during waking hours.

The Norketamine Factor

Norketamine is the primary active metabolite produced when the liver breaks down ketamine. It has distinct receptor binding properties and contributes to both the analgesic and antidepressant effects of ketamine treatment, and it may have a longer half-life than ketamine itself. PubChem's compound summary for ketamine documents this metabolic pathway and the resulting active byproducts.

With IR formulations, norketamine accumulates after each dose and may provide some sustained effect between doses. With ER formulations, the steady production of both ketamine and norketamine creates a more complex but potentially more stable receptor environment. For a closer look at this metabolite, see our explainer on norketamine and its effects.

Current Landscape of ER Ketamine Development

As of 2024, extended-release ketamine tablet formulations were being actively developed by several pharmaceutical companies. These efforts include oral ER tablets designed for once-daily administration in depression maintenance, modified-release capsules for chronic pain with 12-hour coverage, and combination formulations pairing ketamine with other active ingredients.

None of these specialized ER products have yet achieved FDA approval for psychiatric indications. Compounding pharmacies can produce extended-release preparations using established pharmaceutical technology; for more on how these preparations are made, see our guide to compounded ketamine tablets and our overview of FDA considerations for ketamine tablet products.

Practical Considerations for Patients

If you are prescribed a ketamine tablet, ask your prescriber whether you are receiving an IR or ER preparation and why. Understanding the pharmacokinetic profile of your specific formulation helps set appropriate expectations and supports safer, more effective use.